The technologies getting the headlines and the ones already paying off are two different lists.
Ask a biotech leadership team where technology is creating value and most point at drug discovery. Ask their finance team where the returns actually landed this year and the answer sits somewhere far less glamorous. We rated 21 biotech and pharma technologies on the Gartner hype cycle to answer one question for each: is it ready to deploy today, or is it still a bet?
01 Start here
No AI-discovered drug has been approved yet
One fact applies to nearly a third of the technologies in this report, and it should change how you budget for every one of them.
0
AI-discovered, AI-designed or quantum-assisted drugs approved
As of early 2026, by any major regulator
21
technologies rated for this report
The drug discovery half of this list is a bet you are paying a premium to hold. The rest of the article covers what that premium buys — and which technologies are already paying for themselves.
This report summarizes A4BEE's interactive Biotech & Pharma Technology Landscape — filter all 21 technologies by category, region, and maturity.
Open the interactive map02 Ready today
Three technologies that are proven and paying off now
These have become standard practice. There is no return-on-investment debate left — only the question of why anyone is still waiting.
$50-100M
capital cost avoided per single-use facility
Plus up to two years off facility start-up
FDA & EMA
real-world evidence — formal regulatory acceptance
-70°C
cold-chain IoT — the standard the industry now ships vaccines at
- Single-use bioprocessing is the default. For new biologics facilities, removing tens of millions in stainless-steel capital.
- Real-world evidence is the most mature digital technology here. With formal FDA and EMA acceptance already in place.
- Cold-chain IoT became standard overnight. The moment the industry had to ship vaccines at minus 70 degrees.
03 Nearly ready
Three more that regulators are actively validating
Not as settled as single-use bioprocessing, but the FDA and EMA are formally evaluating them, which is the best early signal available.
J&J/Janssen continuous manufacturing: testing-to-release time
| Label | Value |
|---|---|
| Before (batch) | 30days |
| After (continuous) | 10days |
- 33% control-arm reduction. The EMA-qualified PROCOVA digital-twin method for Alzheimer's trials (Unlearn.AI, AAIC 2024).
- Organ-on-chip has active qualification pathways. Both FDA and EMA are formally evaluating it, not just watching from the sidelines.
- De novo protein design already has a Nobel Prize. And a Phase 3 antibody candidate behind it.
04 Still experimental
Big promise, no approvals yet — fund these as bets
Real money and real potential, but no regulatory finish line so far. Fund this group the way pharma already funds early-stage research.
Quantum computing: market today vs. projected value
| Label | Value |
|---|---|
| Market size today | 0.5$B |
| Projected value by 2035 | 350$B |
- AI-designed molecules: candidates in trials, no approvals. The same pattern as the opening number above.
- >$1B in disclosed self-driving-lab VC in 2025. The same year the sector's clearest precedent — Eli Lilly's $90M automated lab from 2017 — was quietly sold off.
- Fund these the way pharma funds a pipeline. Small bets released against milestones, not one large commitment up front.
05 Another view
Ten technologies that are proven and still a competitive edge
Readiness is one measure. Whether a technology still sets you apart is another, and the two do not always line up. These 10 of the 21 clear both bars: proven enough to deploy today, and not yet so widespread that everyone has them.
AI Drug Discovery
Discovery & Design
~$10B in AI/ML pharma deals in 2024 alone.
De Novo Proteins
Discovery & Design
Nobel Prize (2024) plus a Phase 3 generative-antibody asset.
Organ-on-Chip
Preclinical & Lab
FDA roadmap to phase out animal testing for monoclonal antibodies by roughly 2028-2030.
RWD / RWE
Clinical Development
The most mature digital technology in this report.
AI Clinical Trials
Clinical Development
FDA's first qualified AI drug-development tool, December 2025.
Continuous Mfg
Manufacturing & Bioprocessing
J&J: testing-to-release time cut from 30 to 10 days.
CGT Manufacturing
Manufacturing & Bioprocessing
41 FDA-approved cell and gene therapy products as of December 2024.
Automated Cell Therapy
Manufacturing & Bioprocessing
Cellares holds the first FDA Advanced Manufacturing Technology designation.
Perfusion Bioprocess
Manufacturing & Bioprocessing
Modeled at roughly 38% COGS savings versus fed-batch.
Data & Cloud
Enterprise Infrastructure
Pharma and biotech account for roughly 45-60% of life-science cloud end-user share.
These ratings are A4BEE’s own assessment of how proven each technology is and how much it still sets a company apart — not vendor benchmarks. The interactive map above has the full picture, including the 11 technologies that did not clear both bars.
06 The hidden cost
Cybersecurity: the cost every technology here adds
Each of the 21 increases the same exposure. Nobody argues return on investment for this one, because it is a precondition rather than an investment.
Top 5
pharma is a persistent top-five ransomware target
$4.61M
average pharma data breach cost
IBM Cost of a Data Breach, 2025
07 The full picture
Half the list is proven, half is still unproven
One half has a decade of evidence behind it. The other has enormous promise and, so far, no approvals.
0
AI-discovered or quantum-assisted drugs approved
$50-100M
capital cost avoided with single-use (proven today)
30 → 10 days
testing to release, continuous manufacturing (nearly ready)
$4.61M
average data breach cost, a risk all 21 add to
How to split your budget across the two halves
The two halves pay back on very different timescales, so they should be funded differently.
Drug discovery pays back over multiple years and will be settled by trial results in the late 2020s. Manufacturing, lab, and infrastructure technology pay back in 12 to 24 months, and already are for the teams that sorted out their data first. Fund the proven half now, and release money to the experimental half against milestones, the way pharma already funds a research pipeline.
We help manufacturers deploy the proven half: single-use and continuous production lines, the manufacturing digital twin, and the organ-chip and lab data a regulator will actually accept — all built on connected, well-governed data so a pilot can grow past the demo. QB SYSTEMS® handles the lab and bioprocess sensing and integration layer where much of that groundwork starts. Drug discovery will play out on its own timeline. The manufacturing and lab technologies pay back now.
Methodology & sources
This article summarizes A4BEE’s interactive Biotech & Pharma Technology Landscape 2026, which maps all 21 technologies with full source detail, regional breakdowns and named examples — open it to filter by category, region, or maturity. Figures above are drawn from that 21-technology biotech and pharma maturity landscape (2023-2026), McKinsey (pharma AI/ML deal value, manufacturing automation potential, quantum projections), J&J/Janssen’s published Prezista continuous-manufacturing results, Unlearn.AI’s EMA PROCOVA qualification (AAIC 2024), Cellares’ FDA Advanced Manufacturing Technology designation (April 2025), and IBM’s Cost of a Data Breach report (2025). Market-size and valuation figures are third-party estimates and self-reported where sourced from vendors — treat them as directional, not benchmarks to hold a specific program against.